nach oben

Erschienen in:

06.04.2018 | Original Article

Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients

verfasst von: Verónica González-Calle, Abigail Slack, Niamh Keane, Susan Luft, Kathryn E. Pearce, Rhett P. Ketterling, Tania Jain, Sintosebastian Chirackal, Craig Reeder, Joseph Mikhael, Pierre Noel, Angela Mayo, Roberta H. Adams, Gregory Ahmann, Esteban Braggio, A. Keith Stewart, P. Leif Bergsagel, Scott A. Van Wier, Rafael Fonseca

Erschienen in: Annals of Hematology | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

The International Myeloma Working Group has proposed the Revised International Staging System (R-ISS) for risk stratification of multiple myeloma (MM) patients. There are a limited number of studies that have validated this risk model in the autologous stem cell transplant (ASCT) setting. In this retrospective study, we evaluated the applicability and value for predicting survival of the R-ISS model in 134 MM patients treated with new agents and ASCT at the Mayo Clinic in Arizona and the University Hospital of Salamanca in Spain. The patients were reclassified at diagnosis according to the R-ISS: 44 patients (33%) had stage I, 75 (56%) had stage II, and 15 (11%) had stage III. After a median follow-up of 60 months, R-ISS assessed at diagnosis was an independent predictor for overall survival (OS) after ASCT, with median OS not reached, 111 and 37 months for R-ISS I, II and III, respectively (P < 0.001). We also found that patients belonging to R-ISS II and having high-risk chromosomal abnormalities (CA) had a significant shorter median OS than those with R-ISS II without CA: 70 vs. 111 months, respectively. Therefore, this study lends further support for the R-ISS as a reliable prognostic tool for estimating survival in transplant myeloma patients and suggests the importance of high-risk CA in the R-ISS II group.

Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5):2516–2520. https://doi.org/10.1182/blood-2007-10-116129 CrossRefPubMedPubMedCentral

Fonseca R, Abouzaid S, Bonafede M, Cai Q, Parikh K, Cosler L, Richardson P (2017) Trends in overall survival and costs of multiple myeloma, 2000-2014. Leukemia 31:1915–1921. https://doi.org/10.1038/leu.2016.380 CrossRefPubMedPubMedCentral

Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, Pezzatti S, Caravita T, Cerrato C, Ribakovsky E, Genuardi M, Cafro A, Marcatti M, Catalano L, Offidani M, Carella AM, Zamagni E, Patriarca F, Musto P, Evangelista A, Ciccone G, Omede P, Crippa C, Corradini P, Nagler A, Boccadoro M, Cavo M (2014) Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 371(10):895–905. https://doi.org/10.1056/NEJMoa1402888 CrossRefPubMed

Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, Siniscalchi A, Magarotto V, Pour L, Carella A, Malfitano A, Petro D, Evangelista A, Spada S, Pescosta N, Omede P, Campbell P, Liberati AM, Offidani M, Ria R, Pulini S, Patriarca F, Hajek R, Spencer A, Boccadoro M, Palumbo A (2015) Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol 16(16):1617–1629. https://doi.org/10.1016/s1470-2045(15)00389-7 CrossRefPubMed

Biran N, Jacobus S, Vesole DH, Callander NS, Fonseca R, Williams ME, Abonour R, Katz MS, Rajkumar SV, Greipp PR, Siegel DS (2016) Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up. Blood Cancer J 6(9):e466. https://doi.org/10.1038/bcj.2016.68 CrossRefPubMedPubMedCentral

Cavo M, Palumbo A, Zweegman S, Dimopoulos M, Hajek R, Pantani L (2016) Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): a randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial). J Clin Oncol Off J Am Soc Clin Oncol 34:15CrossRef

Attal M, Lauwers-Cances V, Hulin C, Facon T, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L (2015) Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone du Myelome (IFM/DFCI 2009 trial). Blood 126(23):391–391

Fonseca R, San Miguel J (2007) Prognostic factors and staging in multiple myeloma. Hematol Oncol Clin North Am 21(6):1115–1140, ix. https://doi.org/10.1016/j.hoc.2007.08.010 CrossRefPubMed

Kastritis E, Zervas K, Symeonidis A, Terpos E, Delimbassi S, Anagnostopoulos N, Michali E, Zomas A, Katodritou E, Gika D, Pouli A, Christoulas D, Roussou M, Kartasis Z, Economopoulos T, Dimopoulos MA (2009) Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 23(6):1152–1157. https://doi.org/10.1038/leu.2008.402 CrossRefPubMed

10.

Takamatsu H, Honda S, Miyamoto T, Yokoyama K, Hagiwara S, Ito T, Tomita N, Iida S, Iwasaki T, Sakamaki H, Suzuki R, Sunami K (2015) Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era. Cancer Sci 106(2):179–185. https://doi.org/10.1111/cas.12594 CrossRefPubMedPubMedCentral

11.

Lu J, Liu A, Fu W, Du J, Huang X, Chen W, Hou J (2015) The applicability of the international staging system in Chinese patients with multiple myeloma receiving bortezomib or thalidomide-based regimens as induction therapy: a multicenter analysis. Biomed Res Int 2015:856704. https://doi.org/10.1155/2015/856704 PubMedPubMedCentralCrossRef

12.

Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, Dewald GW, Van Ness B, Van Wier SA, Henderson KJ, Bailey RJ, Greipp PR (2003) Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101(11):4569–4575. https://doi.org/10.1182/blood-2002-10-3017 CrossRefPubMed

13.

Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M, Yakoub-Agha I, Garderet L, Marit G, Michaux L, Voillat L, Renaud M, Grosbois B, Guillerm G, Benboubker L, Monconduit M, Thieblemont C, Casassus P, Caillot D, Stoppa AM, Sotto JJ, Wetterwald M, Dumontet C, Fuzibet JG, Azais I, Dorvaux V, Zandecki M, Bataille R, Minvielle S, Harousseau JL, Facon T, Mathiot C (2007) Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 109(8):3489–3495. https://doi.org/10.1182/blood-2006-08-040410 CrossRefPubMed

14.

Gutierrez NC, Castellanos MV, Martin ML, Mateos MV, Hernandez JM, Fernandez M, Carrera D, Rosinol L, Ribera JM, Ojanguren JM, Palomera L, Gardella S, Escoda L, Hernandez-Boluda JC, Bello JL, de la Rubia J, Lahuerta JJ, San Miguel JF, Group GPS (2007) Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 21(1):143–150. https://doi.org/10.1038/sj.leu.2404413 CrossRefPubMed

15.

Kapoor P, Fonseca R, Rajkumar SV, Sinha S, Gertz MA, Stewart AK, Bergsagel PL, Lacy MQ, Dingli DD, Ketterling RP, Buadi F, Kyle RA, Witzig TE, Greipp PR, Dispenzieri A, Kumar S (2010) Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo Clin Proc 85(6):532–537. https://doi.org/10.4065/mcp.2009.0677 CrossRefPubMedPubMedCentral

16.

Kaufman GP, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Lust JA, Russell S, Go RS, Hwa YL, Kyle RA, Rajkumar SV, Kumar SK (2016) Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma. Leukemia 30(3):633–639. https://doi.org/10.1038/leu.2015.287 CrossRefPubMed

17.

Neben K, Jauch A, Bertsch U, Heiss C, Hielscher T, Seckinger A, Mors T, Muller NZ, Hillengass J, Raab MS, Ho AD, Hose D, Goldschmidt H (2010) Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica 95(7):1150–1157. https://doi.org/10.3324/haematol.2009.016436 CrossRefPubMedPubMedCentral

18.

Avet-Loiseau H, Durie BG, Cavo M, Attal M, Gutierrez N, Haessler J, Goldschmidt H, Hajek R, Lee JH, Sezer O, Barlogie B, Crowley J, Fonseca R, Testoni N, Ross F, Rajkumar SV, Sonneveld P, Lahuerta J, Moreau P, Morgan G (2013) Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an international myeloma working group collaborative project. Leukemia 27(3):711–717. https://doi.org/10.1038/leu.2012.282 CrossRefPubMed

19.

Moreau P, Cavo M, Sonneveld P, Rosinol L, Attal M, Pezzi A, Goldschmidt H, Lahuerta JJ, Marit G, Palumbo A, van der Holt B, Blade J, Petrucci MT, Neben K, san Miguel J, Patriarca F, Lokhorst H, Zamagni E, Hulin C, Gutierrez N, Facon T, Caillot D, Benboubker L, Harousseau JL, Leleu X, Avet-Loiseau H, Mary JY (2014) Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. J Clin Oncol 32(20):2173–2180. https://doi.org/10.1200/jco.2013.53.0329 CrossRefPubMedPubMedCentral

20.

Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P (2015) Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 33(26):2863–2869. https://doi.org/10.1200/jco.2015.61.2267 CrossRefPubMedPubMedCentral

21.

Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV (2006) International uniform response criteria for multiple myeloma. Leukemia 20(9):1467–1473. https://doi.org/10.1038/sj.leu.2404284 CrossRefPubMed

22.

Jimenez-Zepeda VH, Duggan P, Neri P, Rashid-Kolvear F, Tay J, Bahlis NJ (2016) Revised international staging system applied to real world multiple myeloma patients. Clin Lymphoma Myeloma Leuk 16(9):511–518. https://doi.org/10.1016/j.clml.2016.06.001 CrossRefPubMed

23.

Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Migkou M, Eleutherakis-Papaiakovou E, Fotiou D, Ziogas D, Panagiotidis I, Kafantari E, Giannouli S, Zomas A, Konstantopoulos K, Dimopoulos MA (2016) Evaluation of the Revised International Staging System (R-ISS) in an independent cohort of unselected patients with multiple myeloma. Haematologica 102:593–599. https://doi.org/10.3324/haematol.2016.145078 CrossRefPubMed

24.

Tandon N, Rajkumar SV, LaPlant B, Pettinger A, Lacy MQ, Dispenzieri A, Buadi FK, Gertz MA, Hayman SR, Leung N, Go RS, Dingli D, Kapoor P, Lin Y, Hwa YL, Fonder AL, Hobbs MA, Zeldenrust SR, Lust JA, Gonsalves WI, Russell SJ, Kumar SK (2017) Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. Blood Cancer J 7(2):e528. https://doi.org/10.1038/bcj.2017.13 CrossRefPubMedPubMedCentral

25.

Walker I, Coady A, Neat M, Ladon D, Benjamin R, El-Najjar I, Kazmi M, Schey S, Streetly M (2016) Is the revised international staging system for myeloma valid in a real world population? Br J Haematol 180:451–454. https://doi.org/10.1111/bjh.14341 CrossRefPubMed

26.

Cho H, Yoon DH, Lee JB, Kim SY, Moon JH, Do YR, Lee JH, Park Y, Lee HS, Eom HS, Shin HJ, Min CK, Kim JS (2017) Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy. Am J Hematol 92(12):1280–1286. doi:https://doi.org/10.1002/ajh.24891

27.

Bataille R, Annweiler C, Beauchet O (2013) Multiple myeloma international staging system: “staging” or simply “aging” system? Clin Lymphoma Myeloma Leuk 13(6):635–637. https://doi.org/10.1016/j.clml.2013.07.003 CrossRefPubMed

28.

Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksac M, Anderson KC, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, Kumar S, Giralt S, Munshi NC, Jagannath S (2011) Consensus recommendations for standard investigative workup: report of the international myeloma workshop consensus panel 3. Blood 117(18):4701–4705. https://doi.org/10.1182/blood-2010-10-299529 CrossRefPubMed

29.

Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, Chen-Kiang S, Durie BG, Carrasco R, Sezer O, Reiman T, Pilarski L, Avet-Loiseau H (2009) International myeloma working group molecular classification of multiple myeloma: spotlight review. Leukemia 23(12):2210–2221. https://doi.org/10.1038/leu.2009.174 CrossRefPubMedPubMedCentral

30.

Lahuerta JJ, Mateos MV, Martinez-Lopez J, Rosinol L, Sureda A, de la Rubia J, Garcia-Larana J, Martinez-Martinez R, Hernandez-Garcia MT, Carrera D, Besalduch J, de Arriba F, Ribera JM, Escoda L, Hernandez-Ruiz B, Garcia-Frade J, Rivas-Gonzalez C, Alegre A, Blade J, San Miguel JF (2008) Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol Off J Am Soc Clin Oncol 26(35):5775–5782. https://doi.org/10.1200/JCO.2008.17.9721 CrossRef

31.

Harousseau JL, Attal M, Avet-Loiseau H (2009) The role of complete response in multiple myeloma. Blood 114(15):3139–3146. https://doi.org/10.1182/blood-2009-03-201053 CrossRefPubMed

32.

Majithia N, Rajkumar SV, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA, Hayman SR, Dingli D, Kapoor P, Hwa L, Lust JA, Russell SJ, Go RS, Kyle RA, Kumar SK (2016) Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia 30(11):2208–2213. https://doi.org/10.1038/leu.2016.147 CrossRefPubMedPubMedCentral

Titel: Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients
verfasst von: Verónica González-Calle
Abigail Slack
Niamh Keane
Susan Luft
Kathryn E. Pearce
Rhett P. Ketterling
Tania Jain
Sintosebastian Chirackal
Craig Reeder
Joseph Mikhael
Pierre Noel
Angela Mayo
Roberta H. Adams
Gregory Ahmann
Esteban Braggio
A. Keith Stewart
P. Leif Bergsagel
Scott A. Van Wier
Rafael Fonseca
Publikationsdatum: 06.04.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 8/2018
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-018-3316-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2018

Necrobiotic xanthogranuloma: a 30-year single-center experience

Temporal trajectory of quality of life and its predictors in recipients of hematopoietic stem cell transplantation

Diffuse large B cell lymphoma (DLBCL): bilateral vanishing tibiae

BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation

Clinical impact of underweight status at diagnosis on elderly patients with acute myeloid leukemia: a retrospective study of JALSG GML200

Efficacy and safety of decitabine against cutaneous granuloblastic sarcoma: a case report

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Update Innere Medizin